<DOC>
	<DOCNO>NCT00004645</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate effectiveness plasma exchange treatment acute severe attack inflammatory demyelinate disease patient fail intravenous steroid therapy .</brief_summary>
	<brief_title>Phase III Randomized , Double-Blind , Sham-Controlled Study Plasma Exchange Acute Severe Attacks Inflammatory Demyelinating Disease Refractory Intravenous Methylprednisolone</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients stratify disease type ; stratum randomize separately . The first group patient receive true plasma exchange use continuous-flow centrifugation serum albumin crystalloid replacement every 2 day total 7 exchange . The second group receive sham plasma exchange centrifugation every 2 day total 7 exchange . Patients cross alternate therapy less moderate improvement day 14 . The treatment decision base blind neurologic assessment . Concurrent corticosteroid immunosuppressant , high-dose barbiturate allow . Patients follow 1 6 month last exchange .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Myelitis</mesh_term>
	<mesh_term>Encephalomyelitis</mesh_term>
	<mesh_term>Myelitis , Transverse</mesh_term>
	<mesh_term>Demyelinating Diseases</mesh_term>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<mesh_term>Encephalomyelitis , Acute Disseminated</mesh_term>
	<mesh_term>Diffuse Cerebral Sclerosis Schilder</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Idiopathic inflammatory demyelinate syndrome , follow : biopsyproven necessary establish diagnosis multiple sclerosis ( MS ) use Poser criterion ; acute disseminate encephalomyelitis ; Marburg 's variant MS Balo 's concentric sclerosis Eligible without biopsy : acute transverse myelitis ; Devic 's syndrome Acute neurologic deficit markedly affect consciousness , language , brainstem/spinal cord function , i.e. , aphasia , paraplegia , coma , quadriplegia , hemiplegia , severe organic brain syndrome Deficit unresponsive 5 day highdose intravenous methylprednisolone ( MePRDL ) , follow : deficit duration 21 day 3 month AND improvement 14 day begin MePRDL OR deficit duration 12 20 day AND continue deterioration completion MePRDL No chronically progressive demyelinate disease No HIVassociated demyelinate syndrome No progressive multifocal leukoencephalopathy No optic neuritis Prior/Concurrent Therapy No 3 month prior steroid therapy Failure prior MePRDL require Minimum dose 7 mg/kg per day 5 day At least 6 week since immunosuppressive , e.g. , cyclophosphamide , azathioprine , cyclosporine Patient Characteristics Renal : Creatinine le 1.5 mg/dL Cardiovascular : No hypovolemia ; infarction ; vasculitis ; major systemic cardiovascular illness Pulmonary : No major respiratory illness Other : No infection , include hepatitis human immunodeficiency virus ; recent intravenous drug abuse ; highrisk sexual behavior ; cardiac , cerebrovascular , autonomic dysfunction would increase risk hypotension ; major systemic illness would preclude protocol therapy ; pregnant nursing woman ; negative serum pregnancy test require fertile woman ; effective contraception require</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>Balo 's concentric sclerosis</keyword>
	<keyword>Devic 's syndrome</keyword>
	<keyword>Marburg 's variant multiple sclerosis</keyword>
	<keyword>acute disseminate encephalomyelitis</keyword>
	<keyword>acute transverse myelitis</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>